Search
-
Pandemic 2009 Influenza Update: Pandemrix™ data on co-administration with annual seasonal influenza vaccine (Fluarix®)
Media
The trial involves 168 adults aged over 60 years of age, and was designed to evaluate the tolerability and immunogenicity.
https://www.gsk.com/en-gb/media/press-releases/pandemic-2009-influenza-update-pandemrix-data-on-co-administration-with-annual-seasonal-influenza-vaccine-fluarix/
First published: 09 November 2009
-
GlaxoSmithKline update: influenza A (H1N1)
Media
GSK committed to supporting governments and health authorities around the world to respond to the emergence of the new H1N1 strain.
https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-influenza-a-h1n1/
First published: 30 April 2009
-
GSK’s respiratory syncytial virus older adult vaccine candidate gains positive European Medicines Agency CHMP opinion
Media
Positive opinion advances GSK’s goal to provide the first vaccine to help protect older adults from respiratory syncytial virus disease
https://www.gsk.com/en-gb/media/press-releases/gsk-s-respiratory-syncytial-virus-older-adult-vaccine-candidate-gains-positive-european-medicines-agency-chmp-opinion/
First published: 27 April 2023
-
Pandemic (H1N1) 2009 Influenza Update: Initial results from first clinical trial of GSK’s H1N1 adjuvanted vaccine
Media
GlaxoSmithKline (GSK) today announced results from its first clinical trial assessing use of its pandemic (H1N1) adjuvanted vaccine.
https://www.gsk.com/en-gb/media/press-releases/pandemic-h1n1-2009-influenza-update-initial-results-from-first-clinical-trial-of-gsk-s-h1n1-adjuvanted-vaccine/
First published: 14 September 2009
-
US FDA Advisory Committee votes to support effectiveness and safety of GSK’s respiratory syncytial virus older adult vaccine candidate
Media
Committee votes unanimously that the data support the effectiveness of the vaccine and 10-2 that the data support the safety of the vaccine
https://www.gsk.com/en-gb/media/press-releases/us-fda-advisory-committee-votes-to-support-effectiveness-and-safety-of-gsk-s-rsv-older-adult-vaccine-candidate/
First published: 01 March 2023
-
GSK welcomes key agreement to support global preparedness against pandemic influenza
Media
GSK welcomes agreement reached at OEWG coordinated by WHO on a Framework to support global preparedness for a future influenza pandemic.
https://www.gsk.com/en-gb/media/press-releases/gsk-welcomes-key-agreement-to-support-global-preparedness-against-pandemic-influenza/
First published: 18 April 2011
-
Regulatory Update: GSK announces submissions for two influenza vaccines
Media
GSK announced today that it has submitted regulatory files for two of its influenza vaccines currently in development.
https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-submissions-for-two-influenza-vaccines/
First published: 05 March 2012
-
GSK shares positive data for Arexvy, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons
Media
Results from the ongoing AReSVi-006 phase III trial show vaccine efficacy over two full seasons
https://www.gsk.com/en-gb/media/press-releases/gsk-shares-positive-data-for-arexvy-its-respiratory-syncytial-virus-older-adult-vaccine-indicating-protection-over-two-rsv-seasons/
First published: 21 June 2023
-
GSK announces US regulatory submission seeking expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 mos+
Media
This vaccine is currently approved for active immunisation against influenza A subtype viruses and type B viruses
https://www.gsk.com/en-gb/media/press-releases/gsk-announces-us-regulatory-submission-seeking-expanded-indication-for-flulaval-quadrivalent-influenza-vaccine-for-infants-6-mosplus/
First published: 02 February 2016
-
GSK receives European approval for expanded indication for Fluarix Tetra (Influenza Vaccine) for ages six months and older
Media
GSK announced the expanded indication for Fluarix Tetra has been approved in Europe.
https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-approval-for-expanded-indication-for-fluarix-tetra-influenza-vaccine-for-ages-six-months-and-older/
First published: 15 February 2018